{"id":"placebo-to-match-zasocitinib","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T12:46:51.717820","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not have any active pharmacological effects. Its purpose is to serve as a control group in clinical trials, allowing researchers to compare the efficacy of zasocitinib against a baseline.","oneSentence":"This drug is a placebo used to match the effects of zasocitinib.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:53.617Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT07108283","phase":"PHASE2","title":"A Study of Zasocitinib in Adults With Nonsegmental Vitiligo","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-11-03","conditions":"Nonsegmental Vitiligo","enrollment":200},{"nctId":"NCT06254950","phase":"PHASE2","title":"A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-03-29","conditions":"Ulcerative Colitis","enrollment":207},{"nctId":"NCT06671483","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-03","conditions":"Psoriatic Arthritis","enrollment":1088},{"nctId":"NCT07250802","phase":"PHASE3","title":"A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-12-04","conditions":"Plaque Psoriasis","enrollment":110},{"nctId":"NCT06671496","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-10","conditions":"Psoriatic Arthritis","enrollment":600},{"nctId":"NCT06233461","phase":"PHASE2","title":"A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-03-05","conditions":"Crohn's Disease","enrollment":268},{"nctId":"NCT06973291","phase":"PHASE3","title":"A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2025-07-09","conditions":"Plaque Psoriasis","enrollment":606}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match zasocitinib","genericName":"Placebo to match zasocitinib","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}